Hempnewsbreaks Lexaria Bioscience Corp. (NASDAQ: LEXX) Engages CRO For Dehydratech GLP-1 Human Study

(MENAFN- Investor Brand Network) Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced it has hired a contract research organization (“CRO”) to oversee execution of the company's 12-week chronic study GLP-1-H24-4. The study will evaluate various DehydraTECH-GLP-1 (glucagon-like peptide) formulations and other treatments with efficacy objectives of weight loss, blood sugar reduction and more.“This study will be the most comprehensive and impactful GLP-1 investigation that Lexaria has ever undertaken,” said John Docherty, president of Lexaria.“The greatly expanded scope compared to our previous studies will allow us to investigate DehydraTECH-GLP-1 safety and efficacy over an extended treatment duration to significantly broaden our knowledge of DehydraTECH's ability to potentially improve the effectiveness and tolerability of this world-leading class of drugs.”

To view the full press release, visit

About Lexaria Bioscience Corp.

DehydraTECH(TM) is Lexaria's patented drug delivery formulation and processing platform technology that improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 43 patents granted and many patents pending worldwide. For more information, visit the company's website at
.

NOTE TO INVESTORS:
The latest news and updates relating to LEXX are available in the company's newsroom at

About HempWire

HempWire
(“HW”) is a specialized communications platform with a focus on hemp-related news, information, and the latest developments in the hemp sector.
HempWire
is one of 60+ brands within
the
Dynamic Brand Portfolio
@
IBN
that delivers :
(1) access to a vast network of wire solutions via
InvestorWire
to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ;
(2) article and
editorial syndication to 5,000+ outlets ;
(3) enhanced
press release enhancement
to ensure maximum impact ;
(4)
social media distribution
via IBN to millions of social media followers ;
and (5) a full array of tailored
corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, HW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, HW brings its clients unparalleled recognition and brand awareness. HW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from HempWire, text“HempWire” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the HempWire website applicable to all content provided by HW, wherever published or re-published:
/Disclaimer

HempWire
Denver, Colorado

303.498.7722 Office
[email protected]

HempWire is powered by
IBN

MENAFN01112024000224011066ID1108840751